CD44st基因在非小细胞肺癌组织中的表达及其意义  

Significance of CD44st gene expression in non-small cell lung carcinoma cancer

作　　者：房新建[1] 张磊[1] 孟祥启[2] 蒋华[1] 

机构地区：[1]连云港市第二人民医院蚌埠医学院附属连云港医院肿瘤内科,222023 [2]连云港市赣榆县人民医院外一科

出　　处：《肿瘤研究与临床》2015年第4期238-242,共5页Cancer Research and Clinic

基　　金：江苏看333人才资助项目（BRA2014117）;江苏省连云港市科技局课题（SH1125）;江苏省连云港市卫生局课题（1115）

摘　　要：目的 检测一种新CD44st基因mRNA在非小细胞肺癌（NSCLC）组织的表达并探讨其临床意义.方法 依据在乳腺癌耐药细胞株研究中发现的CD44st基因mRNA（Gene Bank NO.FJ216964）设计特异性引物序列,应用半定量反转录PCR（RT-PCR）方法、基因测序方法及实时荧光定量PCR（QRT-PCR）方法检测并验证CD44st基因mRNA在83例NSCLC患者（腺癌47例,鳞状细胞癌36例）癌组织及癌旁组织的表达,并分析其与临床病理学特征的关系.结果 NSCLC组织中,CD44stmRNA表达阳性53例（63.9％）,癌旁组织中,均未见CD44st mRNA（P＜ 0.001）.基因测序结果显示：CD44st基因mRNA序列与研究组在MCF-7/Adr细胞中发现的CD44st基因mRNA序列一致.CD44stmRNA表达与患者的分化程度及肿瘤大小无关（P＞ 0.05）;CD44st mRNA在鳞状细胞癌组织中表达高于腺癌,与淋巴结转移及TNM分期相关（P＜0.05）.CD44st mRNA低表达组患者2年内疾病进展或死亡率为45.2％（19/42）,病情稳定率为54.8％（23/42）,CD44st高表达组疾病进展或死亡率为68.3％（28/41）,病情稳定率为31.7％（13/41）,两组差异有统计学意义（P＜0.05）.结论 CD44st基因mRNA在NSCLC组织中高表达与组织病理分类、淋巴结转移及肿瘤分期密切相关,并影响着患者的预后.针对该分子靶点的检测及治疗对于NSCLC患者可能是一种有益选择.Objective To investigate the clinical significance of CD44st expression in non-small cell lung carcinoma （NSCLC）.Methods Specific primers for the CD44st gene （Gene Bank NO.FJ216964） which was found in multidrug resistance cells were designed,and reverse transcription-polymerase chain reaction （RT-PCR）,gene sequencing and real-time PCR were used to validate the expression of the CD44st in the tissues and cancer adjacent tissues of 83 NSCLC patients （47 cases of adenocarcinoma,36 cases of squamous carcinoma）.The clinicopathologic features were analyzed by statistical analysis method.Results The positive expressive rate of CD44st gene mRNA in NSCLC tissue was 63.9 ％ （53/83） and the negative expressive rate was 36.1％ （30/83）,which were more higher than those of cancer adjacent tissues （0/30,0 ％） （P ＜ 0.001）.DNA sequencing results showed that the sequence of CD44st mRNA was consistent with the CD44st mRNA found in MCF-7/Adr cells in our previous study.Expression of CD44st was closely associated with pathological pattern,lymphatic metastasis and TNM staging in NSCLC （P ＜ 0.05）,but not with tumor size and differentiated degree （P ＞ 0.05）.The rates of two years disease progression and stable condition in the group of lower CD44st expression were 45.2 ％ （19/42） and 54.8 ％ （23/42）,respectively,and the rates in the group of higher CD44st expression were 68.3 ％ （28/41） and 31.7 ％ （13/41）,respectively （P ＜ 0.05）.Conclusions The expression level of CD44st is closely related to pathological pattern,the lymph node metastasis and the TNM-staging in NSCLC patients,which seriously influences the prognosis of the NSCLC patients.Therefore,the detection and the therapy to this special target may be a beneficial choice for the prognostic prediction of NSCLC.

关 键 词：CD44st 癌 非小细胞肺 预后 

分 类 号：R734.2[医药卫生—肿瘤]